Cannabis Culture
Cannabis Culture
Study finds little support for cannabis impacting cognitive abilities

Study finds little support for cannabis impacting cognitive abilities
BOULDER, Colo. — The occasional use of cannabis during late adolescence is not independently associated with adverse effects on cognitive abilities in young adulthood, according to longitudinal data published in the journal Drug and Alcohol Dependence.
A team of investigators affiliated with the University of Colorado at Boulder assessed the impact of cannabis use on cognition, executive function, and working memory in 856 individual twins. Cannabis consumers were compared to their non-using twins in late adolescence and then again in their early twenties. Most of the cannabis consuming participants in the study reported occasional use of the substance, but not daily use.
Authors found “little support for a causal effect of cannabis use on cognition. This conclusion is consistent with those from previous twin studies, which suggest that cannabis use does not cause a decline in cognitive ability among a normative cannabis using sample.”
They concluded, “Results suggest that cannabis use may not cause decline in cognitive ability among a normative sample of cannabis users.”
The findings are consistent with several prior studies which also failed to show significant changes in either cognitive performance, brain morphology, or intelligence quotient due to cannabis exposure. Specifically, a 2018 literature review published in JAMA Psychiatry concluded: “Associations between cannabis use and cognitive functioning in cross-sectional studies of adolescents and young adults are small and may be of questionable clinical importance for most individuals. Furthermore, abstinence of longer than 72 hours diminishes cognitive deficits associated with cannabis use.”
Minn. regulators to expand medical cannabis access
ST. PAUL, Minn. — Health Department representatives have announced forthcoming changes to the state’s medical cannabis program in an effort to expand patients’ access.
Beginning in August 2020, those diagnosed with chronic pain and/or age-related macular degeneration will be eligible to receive medical cannabis recommendations.
Regulators are also amending the program to allow cannabis products to be sold in the form of powders, gum, lozenges, and sublingual tablets, among other formulations. State law does not allow for the sale of herbal cannabis.
Officials also announced that they would be expanding the total number of licensed dispensaries operating within the state.
An estimated 18,000 Minnesotans are registered to legally access medical cannabis products.
Potency of CBD products often mislabeled
SEATTLE — The percentage of cannabidiol present in many commercially available CBD products differs from what is advertised on the label, according to an analysis commissioned by Leafly.com.
Authors lab tested 47 commercially available CBD-infused products. Products were purchased either online, at drug store chains, or at independent grocery stores.
Twenty-three percent of the products possessed significantly lower percentages of CBD than advertised, a finding that is consistent with prior reports. An additional 11 percent of products contained no identifiable level of CBD. Fifteen percent of the products contained higher percentages of CBD than advertised.
CBD-infused tinctures and edibles were most likely to possess accurate labeling. By contrast, CBD-infused capsules and water-based products were the least likely to be accurately labeled.
Currently, the U.S. Food and Drug Administration provides no regulatory oversight on commercially available CBD products.
Medical cannabis well tolerated in older patients: study
BE’ER-SHEVA, Israel — The use of herbal cannabis by older patients is efficacious and well-tolerated, according to longitudinal data published in the Journal of Clinical Medicine.
Israeli researchers assessed the use of cannabis products in patients ages 65 or older over a period of 18 months. Participants in the trial suffered from cancer, chronic pain, sleep disorders, post-traumatic stress, spasticity, and other ailments.
Of those patients who continued the use of medical cannabis for six-months or more, 79 percent reported either “significant” or “moderate improvement” from the treatment. The most commonly reported side effects of cannabis treatment were dizziness, fatigue, and dry mouth.
Authors concluded, “Our results show that cannabis was well tolerated by most of our patients… [and that] most of the patients were satisfied with the treatment.”
The findings are consistent with those of prior trials similarly finding that cannabis preparations are safe and effective for elderly patients.
Cannabis Culture news in the Blade is provided in partnership with NORML. For more information, visit norml.org.
Cannabis Culture
LGBTQ people, weed, and mental health: what you need to know
Community uses marijuana at much higher rates than general population
Uncloseted Media published this story on May 7.
By SPENCER MACNAUGHTON | In 2025, the global cannabis market size was valued at nearly $103 billion. By 2034, that number is expected to explode by roughly 1,400 percent to more than $1.43 trillion.
In short, as an increasing number of countries legalize marijuana use, everyone is starting to consume a lot more weed. And LGBTQ people tend to use cannabis at much higher rates than the general population. One study found that 55 percent of lesbian and 45 percent of gay young adults use marijuana, compared to about 33 percent and 37 percent, respectively, of their straight counterparts.
As LGBTQ people face a mental health crisis, the mainstream stereotypes that depict weed as an antidote for anxiety, panic and depression aren’t painting the full picture. And that could be exacerbating the mental health struggles so many queer people, and especially youth, face.
Here’s what the research demonstrates about marijuana and its effects on mental health:
- Multiple studies suggest a link between marijuana use and an increased risk of mental health disorders, including schizophrenia, depression and anxiety in individuals who are genetically predisposed.
- One study found that daily marijuana use, especially among younger people, makes some individuals seven times more likely to develop psychosis.
The increase in higher-potency strains of marijuana could pose unknown risks. In 1995, the average content of Tetrahydrocannabinol (THC) in confiscated marijuana was less than 4 percent. In 2022, it was more than 16 percent. Researchers don’t know the full extent of the impact that these higher concentrations can have on mental health and especially on younger people whose brains are still developing.
- A systematic review of studies published between 2013 and 2025 found damning results for the mental health of young cannabis users:
They were 51 percent more likely to experience depression, 58 percent more likely to experience anxiety, between 50 and 65 percent more likely to experience suicidal ideation and 80 to 87 percent more likely to have attempted suicide.
- While the above stats paint a grim picture, there is also some research that suggests benefits of cannabis use:
- A 2025 systematic review found that “medicinal” weed showed some efficacy in relieving withdrawal symptoms of opioid use disorder. THC use has been associated with improvement of post-traumatic stress disorder symptoms, bipolar symptoms and sleep quality.
- Other studies found that THC administered in a controlled setting was associated with a decrease of symptoms and adverse effects for a range of mental health disorders, including schizophrenia, psychotic symptoms, and anorexia nervosa.
Beyond what we pulled from academia, there is an astounding lack of information about the interplay between weed and mental health. As we dive deeper into Mental Health Awareness Month, I hope advocacy organizations, influencers and news outlets ramp up their coverage of this important topic that affects the countless LGBTQ weed smokers, many of whom are already struggling.
Democratic Gov. Michelle Lujan Grisham earlier this month signed two separate measures into law amending the state’s marijuana policies. The first measure (House Bill 2) legalizes and regulates marijuana possession, production, and sales for adults. The second measure (Senate Bill 2) facilitates the automatic review and expungement of the records of those convicted of low-level marijuana offenses.
Lawmakers approved both bills during a special legislative session demanded by Gov. Lujan Grisham, who had been a vocal proponent of the reforms.
NORML State Policies Manager Carly Wolf said: “This is a day to celebrate! New Mexico will greatly benefit from this new revenue stream and the creation of thousands of jobs. Most notably though, legalization will spare thousands of otherwise law-abiding residents from arrest and a criminal record, and the state’s new expungement law will help provide relief to many who are suffering from the stigma and other collateral consequences associated with a prior marijuana conviction.”
The adult-use measure (House Bill 2) permits those ages 21 and older to legally purchase up to two ounces of marijuana and/or up to 16 grams of cannabis extract from licensed retailers. It also permits adults to home-cultivate up to six mature plants for their own personal use. Retail sales would begin by April 2022.
The expungement measure (Senate Bill 2) stipulates that those with past convictions for offenses made legal under this act are eligible for automatic expungement of their records. Those currently incarcerated for such offenses are eligible for a dismissal of their sentence. It’s estimated that over 150,000 New Mexico residents are eligible for automatic expungement under this measure, according to the Department of Public Safety.
Cannabis Culture news in the Blade is provided in partnership with NORML. Visit norml.org for more information.
Cannabis Culture
Delaware cannabis activists take on corporate marijuana
Criticism from medical marijuana operators claimed that HB150 offers too many cultivation and retail licenses
As the country moves forward with sweeping changes in cannabis policy reform, locals in Delaware are tangling with corporate, multi-state medical marijuana permit holders to pass a bill for full legalization.
Adult-use activists and registered medical patients were stunned to hear opposing testimony from Delaware’s medical marijuana operators. Patients already deal with limited access and costly products. Now, many see the established industry voicing opposition as simply obstructing the progress of adult-use legislation. In response, some patients are now staging a boycott of the regulated dispensaries.
During the first committee hearing for HB150, Delaware’s adult-use bill, four of the state’s six currently licensed, multi-million dollar medical cannabis facilities offered negative testimony.
Zoë Patchell, executive director of Delaware CAN responded: “This market belongs to the long-time consumers, patients, and activists. We create the demand, we’ve been the ones driving the reform efforts, and we pay the prices at dispensaries. Cannabis is more than a market – cannabis is a community. These companies cannot reasonably fathom that we are going to purchase cannabis from any entity that has proven to put profits over patients. And now they seem willing to put consumers’ lives and freedom at risk just to hold out for an unfair advantage in the industry.”
These included publicly traded Columbia Care, “Fresh Delaware” aka CCRI, CannTech Research Inc., and the owner of EZY Venture aka “The Farm.”
They all went on record condemning HB150, and pushing a false narrative about oversupply. The core demand from the permit cartel was some protection for their private business interests with guaranteed adult-use licenses.
Criticism from the medical marijuana operators claimed that HB150 offers too many new cultivation and retail licenses, underlined by deep yet unfounded fears that the new competition would put their companies out of business.
Patchell noted, “We are not going to sit back while multi-state corporate entities, that already monopolize East Coast medical markets, work to undermine our social equity and micro-license provisions.”
Cannabis Culture news in the Blade is provided in partnership with NORML. Visit norml.org for more information.
-
Commentary5 days agoHow do you vote a child out of their future?
-
New York5 days agoGay ICE detainee freed after 150 days in detention
-
Arts & Entertainment4 days agoA reign defined by commitment and human impact
-
Ukraine4 days agoUkrainian MPs advance new Civil Code without protections for same-sex couples
